Targets › CYP2D6
2 programs from 2 companies in 3 trials: 3 Phase 4; Infectious disease.
A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). (UniProt, P10635)
Open in Phaseline: the race on CYP2D6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shoklo Malaria Research Unit | Tafenoquine 8-aminoquinoline; hypnozoitocidal agent targeting liver-stage malaria parasites | CYP2D6 | Phase 4 | Malaria | – |
| Curtin University | Tafenoquine 8-aminoquinoline with activity against hypnozoites and blood stages of Plasmodium vivax | CYP2D6 | Phase 4 | Pharmacokinetics of Tafenoquine | – |
Malaria (2) Pharmacokinetics of Tafenoquine (1)
small molecule (2)
Shoklo Malaria Research Unit (1) Curtin University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.